Methods of treating cancer using compounds containing a vascular disrupting agent
申请人:Ellipses Pharma Limited
公开号:US10912839B2
公开(公告)日:2021-02-09
The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
本发明涉及血管破坏剂的原药,包括与 MMP 蛋白水解裂解位点相关的血管破坏剂 (VDA),以及此类原药在癌症靶向治疗中的应用。